NCODA

NCODA Advancing patient-centered cancer care through collaboration, education, and innovation.

Is Polycythemia Vera Treatment Practice Keeping Pace with the Evidence?NCODA’s new white paper, Shifting Treatment Persp...
09/02/2026

Is Polycythemia Vera Treatment Practice Keeping Pace with the Evidence?

NCODA’s new white paper, Shifting Treatment Perspectives in Polycythemia Vera: Real-World Experience with Ropeginterferon Alfa-2b, prepared by Michelle Taymuree, PharmD, MBA, (NCODA), explores how these changing perspectives are shaping real-world PV care.

Key insights include:
-How clinical perspectives on the role and timing of ropeginterferon alfa-2b are evolving
-Why access, workflow, and patient experience can influence treatment decisions
-Practical strategies to support treatment initiation and long-term management
-How multidisciplinary care and medically integrated pharmacy can address implementation barriers
-What the newly approved BESREMi Pen™ may mean for administration and patient experience

Explore the full white paper: https://bit.ly/3SWnL0o...

09/01/2026

As fall rolls around, there are plenty of opportunities to connect, learn, and grow with NCODA! Explore some of our upcoming webinars and community gatherings covering timely topics and practical insights from across the oncology community:

-OPTA September Webinar — Wed, Sep 9, at 3 PM ET
-Nursing Community Gathering — Fri, Sep 11 at 3 PM
-Urology Clinical Update: Comparing Newly Approved Therapies for NMIBC — Tue, Sep 15 at 2 PM
-Diet & Exercise Role in Cancer Survivorship — Wed, Sep 16 at 2 PM
-Pharmacist Community Gathering — Tue, Sep 29 at 3 PM
-PSO Student Community Gathering — Wed, Sep 30 at 5 PM

View all webinars: https://bit.ly/3PqFfAw

How can medically integrated oncology teams support patients throughout treatment with inavolisib?Our latest PQI in Acti...
08/31/2026

How can medically integrated oncology teams support patients throughout treatment with inavolisib?

Our latest PQI in Action, featuring insights from Duke Health and Cone Health, explores practical strategies for patient selection, proactive adverse event management, patient education, and multidisciplinary care.

Main Takeaways:
🔹 Confirm PIK3CA mutation status and assess prior endocrine therapy, comorbidities, and baseline labs before treatment initiation.
🔹 Be proactive with adverse event prevention and monitoring, especially hyperglycemia, which can occur early in treatment.
🔹 Use a multidisciplinary approach to support patient education, toxicity management, access, and continuity of care throughout therapy.

Explore the full resource: https://bit.ly/45sGKm2

NCODA is heading to Montréal for the 84th International Pharmaceutical Federation (FIP) World Congress of Pharmacy and P...
08/28/2026

NCODA is heading to Montréal for the 84th International Pharmaceutical Federation (FIP) World Congress of Pharmacy and Pharmaceutical Sciences!

Representing NCODA in Montréal will be:

- Mustafa Abacioglu, MPharm
- Jonas Congelli, RPh
- Michael Reff, RPh, MBA
- Stephen Ziter, MBA

Attending FIP Congress 2026? Stop by Booth 51 to meet the NCODA team and learn more about our work to advance patient-centered, medically integrated oncology care around the world.

We look forward to connecting with the global pharmacy community in Canada! Learn More: https://bit.ly/4hNRzXf

We're excited to announce the launch of our new Treatment Support Kit (TSK) for patients receiving Avutometinib and Defa...
08/27/2026

We're excited to announce the launch of our new Treatment Support Kit (TSK) for patients receiving Avutometinib and Defactinib.

This complimentary resource is designed to help patients prepare for treatment, manage their therapy with confidence, and stay organized throughout their treatment journey.

Each Kit includes:
SPF 70 Sunscreen
Hydrocortisone 1% Cream
Educational Booklet
Patient Treatment Calendar

By providing practical resources and educational materials, the Treatment Support Kit helps reinforce patient education while supporting treatment adherence and proactive symptom management: https://bit.ly/4dLI2gH

08/27/2026

On Season 11, Episode 2 of The PQI Podcast, we’re joined by Geoffrey Rogow, Executive Editor of BBC Studios in New York, award-winning journalist, cancer survivor, founder of After Treatment, and author of the upcoming book: I’m Alive. Now What?

Geoffrey shares how his cancer diagnosis at age 30 shaped his life beyond treatment, exploring the challenges of survivorship, finding support and purpose, and preparing patients for what comes next. Listen to the full episode here: https://bit.ly/4uLEPnk

There's still time to nominate or apply for the 2026 NCODA Living the Mission Award!This award recognizes NCODA members ...
08/26/2026

There's still time to nominate or apply for the 2026 NCODA Living the Mission Award!

This award recognizes NCODA members who embody our mission through leadership, collaboration, innovation, and a commitment to advancing high-quality, patient-centered oncology care.

Don't miss the opportunity to celebrate someone making a meaningful impact. Submit your application or nomination today: https://bit.ly/4w0PeMh

TODAY at 2 pm ET: Cabozantinib plus nivolumab remains an important first-line treatment option for advanced renal cell c...
08/26/2026

TODAY at 2 pm ET: Cabozantinib plus nivolumab remains an important first-line treatment option for advanced renal cell carcinoma, but successful treatment goes beyond regimen selection.

Join Jennifer Hasiak, PharmD, of Hematology & Oncology Consultants, as she discusses efficacy and safety data, patient monitoring, adverse reaction management, patient education, and available support resources.

Log in to join: https://ncoda.org/webinars/a-combination-treatment-for-patients-with-advanced-renal-cell-carcinoma-a...

TODAY at 2 pm ET: Join NCODA on August 25 at 2:00 p.m. EST for an educational webinar exploring sacituzumab govitecan-hz...
08/25/2026

TODAY at 2 pm ET: Join NCODA on August 25 at 2:00 p.m. EST for an educational webinar exploring sacituzumab govitecan-hziy in first-line metastatic triple-negative breast cancer (mTNBC).

James Spellman of Gilead Sciences will review the evolving first-line treatment landscape and unmet needs in mTNBC, efficacy and safety findings from the Phase 3 ASCENT-03 and ASCENT-04 studies, and how current evidence and NCCN Guidelines® recommendations can inform treatment selection across PD-L1 status.

Log in to join: https://ncoda.org/webinars/sacituzumab-govitecan-hziy-in-1l-mtncb/

The NCODA Immunotherapy Hub brings together clinical guidance, agent-specific resources, operational tools, SOP examples...
08/24/2026

The NCODA Immunotherapy Hub brings together clinical guidance, agent-specific resources, operational tools, SOP examples, and educational content to help oncology teams navigate dosing, monitoring, toxicity management, and care coordination.

Explore resources designed to support your team at every stage of implementation: https://bit.ly/4fejr56

Address

PO Box 468
Cazenovia, NY
13035

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+1 315-655-4640

Website

Alerts

Be the first to know and let us send you an email when NCODA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to NCODA:

Shortcuts

Share

Category